Nedaplatin

Clinical data
AHFS/Drugs.com	International Drug Names
Routes of administration	IV
ATC code	none
Legal status
Legal status	In general: ℞ (Prescription only)
Identifiers
IUPAC name Diammine[(hydroxy-κO)acetato(2-)-κO]platinum
CAS Number	95734-82-0 Y
PubChem CID	9796440
ChemSpider	7972206
UNII	8UQ3W6JXAN
KEGG	D01416 Y
CompTox Dashboard (EPA)	DTXSID8046878
Chemical and physical data
Formula	C2H8N2O3Pt
Molar mass	303.181 g·mol−1
3D model (JSmol)	Interactive image coordination form: Interactive image
SMILES C(C(=O)[O-])[O-].N.N.[Pt+2] coordination form: O=C1O[Pt-2]([NH3+])([NH3+])OC1
InChI InChI=1S/C2H3O3.2H3N.Pt/c3-1-2(4)5;;;/h1H2,(H,4,5);2*1H3;/q-1;;;+2/p-1 Key:GYAVMUDJCHAASE-UHFFFAOYSA-M
(verify)

Nedaplatin (INN, marketed under the tradename Aqupla) is a platinum-based antineoplastic drug which is used for cancer chemotherapy.^[1] The complex consists of two ammine ligands and the dianion derived from glycolic acid.

Platinum-based drugs are widely employed as antineoplastic agents, especially cisplatin and carboplatin. Due to issues of their toxicity and number of cisplatin-resistant cancer cells, other platinum derivatives have been developed. Nedaplatin is one example of such new drugs.^[2]